Get Even More Visitors To Your Blog, Upgrade To A Business Listing >>

Coronavirus week 121: Vaccine losers

I remember that, more than a year ago, people more knowledgeable than me in fields like immunlogy and even more importantly, warned there would be vaccine losers as well as winners as the race narrowed and government funding and other support picked winners and losers.

Well, as the not-quite-omni but more widely targeted anti-Omicron boosters that Pfizer and Moderna roll out ...

Where's Johnson and Johnson? Ever since the US government paused the administration of the J and J adenovirus based vaccine in April 2021 over what were likely overstated concerns about blood clotting, it's scrambled to stay in the game. And, the FDA since then largely shunted J and J aside. As a result, it had no incentive to work on a COVID booster and instead turned its primary factory in Europe into working on a new experimental non-COVID vaccine.

As a result, we're left only with Mrna Vaxxes for boosters.

Yes, Novavax exists, and it, like older antiviral vaccines against other viruses, directly targets a COVID spike protein. That said, right now, there's not official approval for a one-dose booster, nor do we have information yet on how Novavax performs against Omicron.

I'm not a nutter who believes Mrna Vaxxes alter my RNA, or DNA.

I am someone who notes the relatively rapid falloff in mRNA protection. And, while J and J allegedly had less degree of protection, there's been no reports about the same degree of falloff.

I got it, the first chance I had in my rural area, both because it was a one-shot vax and because it was based on more traditional vaccine technology.

IF I were to want a booster (not old, but not young, either, and I've gotten none so far), I would go Novavax. It and the mRNA vaxxes both themselves have rare coronary side effects, it seems. But, Novavax is a more traditional technology, like J and J, and I venture it has a slower dropoff period than the mRNA vaxxes, like J and J. And, eventually, the more times you get shot, even if they remain very low, the more your chances of some side effect.

AstraZenica is also an adenovirus vax. It, like Johnson and Johnson, also known as Janssen from its Euro subsidiary, has also had very small numbers reported of people with clotting. But, it was never shelved, here or abroad. It and Novavax both have the down side of being two-dose vaxxes in non-booster situations. Other adenovirus vaxxes are Russia's Sputnix and a newer kid, Convidecia. It's one-shot; Sputnik is two. Convidecia, like Sinopharm, which uses dead virus, is Chinese.

There are other "viral vector vaccines" that use vector viruses besides an adenovirus.

And, there's the Indian nasal vaccine (China and others have similar in the pipeline) but based on attempts at nasal flu vaccines here in the US, William Haseltine is highly skeptical.



This post first appeared on SocraticGadfly, please read the originial post: here

Share the post

Coronavirus week 121: Vaccine losers

×

Subscribe to Socraticgadfly

Get updates delivered right to your inbox!

Thank you for your subscription

×